DUBLIN, Dec. 16, 2020 /PRNewswire/ -- Medtronic plc
(NYSE: MDT) announced that the U.S. Food and Drug Administration
(FDA) has cleared the use of navigated interbody and Midas Rex™
high speed drills with the Mazor™ Robotic Guidance System earlier
than originally anticipated. The Mazor™ platform now provides
surgeons with unprecedented procedural integration by seamlessly
combining the power of Midas Rex™ drills with the market leading
visibility and navigation from the StealthStation™ software.
The solution delivers the confidence of access and interbody
navigation and predictability of planning, along with the precision
of robotic technology that surgeons expect from the Mazor™ Robotic
Guidance System and the exclusive Medtronic robotics portfolio.
"Operating rooms are very complex environments, and we look
forward to incorporating new functionality into our Mazor workflow
to enhance the predictability and precision of a broader range of
procedures leading to better patient outcomes," said Dr.
Eiman Shafa of Twin Cities Spine
Center. "The ability to
broaden surgical staff awareness about the procedure plan and
potentially reduce fluoroscopy radiation should also improve our
workflow creating a win-win for all hospital stakeholders."
Medtronic has evolved the Mazor platform to allow surgeons to
quickly visualize anatomy and spinal structures in relation to one
another in 3D. The enhanced interface delivers fast and seamless
access to plan and simulate cages and screws, with the goal of
increasing efficiencies for surgeons. The best-in-class, Midas Rex
High Speed Drill Systems are now fully integrated throughout the
Mazor procedure enabling improved trajectory precision starting
with pilot hole creation and offering attachments and dissecting
tools designed for accurate drilling with speeds up to 75,000 rpm.
Additionally, surgeons can now utilize navigated interbody
features on the Mazor system to visualize disc prep and interbody
placement during a robotic procedure.
"Transforming spinal care is a top priority for Medtronic and we
work closely with customers to develop products that anticipate
their needs," said Linnea Burman, vice president &
general manager, enabling technologies: cranial & spinal
technologies, which is reported as part of the Restorative
Therapies Group at Medtronic. "With these recent clearances,
we have advanced the Mazor platform by increasing its utility,
improving its precision and adding capabilities as we drive toward
our goal of delivering value-driven solutions for unmet needs."
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest
medical technology, services and solutions companies – alleviating
pain, restoring health and extending life for millions of people
around the world. Medtronic employs more than 90,000 people
worldwide, serving physicians, hospitals and patients in more than
150 countries. The company is focused on collaborating with
stakeholders around the world to take healthcare Further,
Together.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Contacts:
|
|
|
|
David T.
Young
|
Ryan
Weispfenning
|
Public
Relations
|
Investor
Relations
|
+1-774-284-2746
|
+1-763-505-4626
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/medtronic-strengthens-leadership-in-navigated-robotic-spine-surgery-with-fda-clearance-of-midas-rex-drills-and-navigated-disc-prep-and-interbodies-for-us-with-mazor-robotic-guidance-system-301194043.html
SOURCE Medtronic plc